The Endocannabinoid System and Cannabidiol’s Role in Stress, Anxiety, and Fear Responses – Part Two
In this second of the two-part feature, Cannabis Health contributor Stuart Tomc leads us in understanding the role Cannabidiol (CBD) plays influencing the Endocannabinoid System, in specific regard to common emotional disorders.
The biological mechanisms that control mood, anxiety, stress, fear, and other emotional behavior have been focused almost exclusively on the role of certain neurotransmitters called monoamines. While monoamines like dopamine, serotonin, and norepinephrine play an important role in controlling mood and anxiety, the vast majority of drug-based therapies that target those “monoaminergic” systems are limited in their efficacy.
More recently, research has begun to highlight other neurochemical systems, including cytokines, peptides, and bioactive lipids. By diving deeper into the science of bioactive lipids, we begin to unearth the potential role of the endocannabinoid system (ECS) in stress and fear responses.
The Endocannabinoid System’s (ECS) Role in the Human Body
The ECS has been described in our previous article as a complex physiologic network within the human body 
comprised of cannabinoid receptors (CB1 and CB2). There are endogenous cannabinoid compounds such as anandamide and 2-AG, and their respective enzymes responsible for maintaining balance in the system by regulating the synthesis and breakdown of the active endocannabinoid compounds.
Not surprisingly, cannabinoid receptors and the biochemical machinery necessary to synthesize and generate cannabinoids are present within areas of the brain known to control emotional behavior, mood, stress, and fear. These structures include the prefrontal cortex, amygdala, hippocampus, and periaqueductal gray (PAG) of the midbrain.
What Happens in the Brain When Cannabinoid Receptors Are Activated?
Preclinical studies in mice have clearly shown that activation of cannabinoid receptors within the periaqueductal gray (PAG) region of the mid-brain (the ‘PAG” is the primary control area of the brain for descending pain modulation) via direct injection of anandamide reduces panic and anxiety behavior, or the “fight or flight” phenomenon. Other studies using a similar model in animals have shown decreased fear-avoidant and conditioned responses to pain or punishment.
However, before we jump the gun and feel like we have fear, anxiety, and stress responses all figured out, it’s not as simple as activating receptors through cannabinoid administration. Other animal studies utilizing systemic injections of Δ9-THC (delta-9) (not directly into the PAG of the midbrain) have demonstrated mixed responses, eliciting either anxiogenic (promoting increased levels of anxiety) or anxiolytic (decreasing levels of anxiety).
This bidirectional or paradoxical response appears to be dose-dependent, where lower doses seem to reduce stress, anxiety, and panic, while higher doses may promote increased feelings of stress, panic, and fear. These opposing effects are likely a result of the involvement of other neurotransmitter circuits within the brain that, when inhibited, actually create a hyper-excitable response of stress, anxiety, and fear.
Striking a Balance within the Cannabinoid System
[quote]The totality of the best available scientific evidence points to the importance of balancing the tone of the endocannabinoid system for supporting a healthy stress response. [/quote]To illustrate what neuroscientists currently feel is happening, think of being in a car with the brake pedal and accelerator. When the cannabinoid system is functioning to decrease fear, stress, and panic, the foot is being taken off of the accelerator in the areas of PAG-midbrain centers.
On the other hand, when dosing is too high, or there is an imbalance in the endocannabinoid system, whereby CB1 receptors are being over-activated in lieu of CB2, that’s like taking the foot off the brake pedal, thereby removing inhibition that was normally in place and allowing the engine to rev higher—increased fear, anxiety, and stress from activation of other circuits in the brain that are normally applying the brake.
More recently, other preclinical research has demonstrated the important role of maintaining a healthy endocannabinoid system “tone” for improved stress resilience and reducing the residual post-traumatic anxiety, fear, and panic behaviors in mice that were chronically exposed to stress. Interestingly, the greater the exposure to stress, the greater the magnitude of the response to treatment by improving the ECS and cannabinoid signaling (communication that governs basic cellular activities and coordinates cell actions).
Are Cannabinoid Compounds the “Gatekeepers” to Healthy Stress Levels?
One theory is that anandamide and 2-AG are acting as “gatekeepers” to keep the stress response and high emotional loads at bay and improving recovery to pre-stress levels once the stress burden is reduced to baseline. Moreover, there is evidence from preliminary human studies that disrupting endocannabinoid signaling and regulation has important impacts on the HPA (hypothalamic-pituitary-adrenal) axis by increasing signs of anxiety and depression.
There is an emerging role in the interplay between the immune system and the neuro-endocrine system, such that the field of psychoneuroimmunology has exploded with new basic and preclinical research over the past 5 years. The crosstalk between the immune system, cytokine signaling, and the nervous system influencing behavior, anxiety, and mood has been proposed by numerous preclinical studies. A number of recent studies have demonstrated a role of CB2 receptors classically associated with the immune system in anxiety and depression-related behavior in animal models and human clinical studies.
In this context, it’s interesting to note that a balanced ECS appears to be pivotal to a healthy stress response and mitigating fear, anxiety, and panic that tend to accumulate with dysfunctional responses to stress.
CBD and Anxiety Reduction in Humans
A randomized, double-blind, placebo controlled trial in 15 humans demonstrated that up to 600 mg of CBD (cannabidiol) reduced measured anxiety compared to increased levels with a 10 mg dose of Δ9-THC. CBD appears to activate other receptors outside CB2, including 5HT1A and TRPV1, both of which are involved in the anxiolytic and mitigating panic/fear responses to stress.
The totality of the best available scientific evidence points to the importance of balancing the tone of the endocannabinoid system for supporting a healthy stress response. This preclinical and emerging human clinical data support the use of a CBD-rich or CBD-overweighted extract of cannabis for modulating fear, anxiety, and a healthy stress response.
[infobox title=’Questions?’]If you have questions about CBD, send them to david@cannabishealth.com or share them via Facebook or Twitter. Our goal is to spread awareness of and education about hemp-derived CBD products, so send us your questions and we’ll address them in future installments![/infobox]
This article is sponsored by CV Sciences, one of the leading suppliers of agricultural hemp derived CBD from seed to finished products.
References:
- Campos AC, Ferreira FR, Guimarães FS. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. J Psychiatr Res. 2012 Nov;46(11):1501-10.
- Campos AC, Guimarães FS. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1517-21.
- Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009 Jan;66(1):95-105.
- Hill MN, Patel S. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol Mood Anxiety Disord. 2013 Oct 22;3(1):19.
- Saito VM, Wotjak CT, Moreira FA. Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders. Rev Bras Psiquiatr. 2010 May;32 Suppl 1:S7-14.
- Witkin JM, Tzavara ET, Nomikos GG. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol. 2005 Sep;16(5-6):315-31.
